Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

Medicenna Therapeutics (MDNA)

Medicenna Therapeutics Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MDNA
DateTimeSourceHeadlineSymbolCompany
14/05/202421:29Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/05/202420:42Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MDNAMedicenna Therapeutics Corporation
13/05/202419:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
30/04/202420:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
26/04/202420:28Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/04/202419:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
22/04/202421:40Edgar (US Regulatory)Form AW - Amendment Withdrawal RequestNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202422:05Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202422:05Edgar (US Regulatory)Form F-3/A - Registration statement by foreign private issuers: [Amend]NASDAQ:MDNAMedicenna Therapeutics Corporation
16/04/202422:04Edgar (US Regulatory)Form F-10POS - Post-effective amendment to a F-10EF registrationNASDAQ:MDNAMedicenna Therapeutics Corporation
09/04/202419:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
04/04/202419:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
14/02/202412:30Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
24/01/202421:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
09/01/202415:33Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
05/01/202414:06Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
22/12/202319:13Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
09/11/202313:56GlobeNewswire Inc.Medicenna to Present 4 Year Follow-up Phase 2b Bizaxofusp Survival Data in Recurrent Glioblastoma at the Society for Neuro-Oncology 2023 Annual MeetingNASDAQ:MDNAMedicenna Therapeutics Corporation
08/11/202315:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
06/11/202312:00GlobeNewswire Inc.Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
03/11/202316:00GlobeNewswire Inc.Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
27/10/202312:55GlobeNewswire Inc.Medicenna Announces Nasdaq Delisting and Cutback of Management TeamNASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202320:51Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
25/10/202312:00GlobeNewswire Inc.Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsNASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202312:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
24/10/202312:15GlobeNewswire Inc.Medicenna Announces Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC)NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202313:57Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
10/10/202312:07GlobeNewswire Inc.Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerNASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202322:00Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MDNAMedicenna Therapeutics Corporation
03/10/202312:00GlobeNewswire Inc.Medicenna Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and ImmunotherapyNASDAQ:MDNAMedicenna Therapeutics Corporation
 Showing the most relevant articles for your search:NASDAQ:MDNA

Your Recent History